Relmada Therapeutics (RLMD) Share-based Compensation (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Share-based Compensation data on file, last reported at $956186.0 in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 73.24% year-over-year to $956186.0 in Q1 2026; TTM through Mar 2026 was $10.3 million, a 59.36% decrease from a year earlier, with the FY2025 full-year figure at $13.9 million, down 53.93% from the prior year.
• Share-based Compensation for Q1 2026 stood at $956186.0, down from $2.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for RLMD reached as high as $12.3 million in Q2 2022 and fell as low as $956186.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $8.0 million across 5 years, with a median of $8.3 million in 2024.
• Across the five-year window, Share-based Compensation soared 103.9% in 2022 and tumbled 73.24% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $11.6 million in 2022, then dropped by 14.9% to $9.9 million in 2023, then plunged by 32.02% to $6.7 million in 2024, then sank by 64.75% to $2.4 million in 2025, then plunged by 59.67% to $956186.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $956186.0 in Q1 2026, $2.4 million in Q4 2025, and $7.7 million in Q3 2025.